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Abstract
Motivated by the recent implication of cysteine protease cathepsin L as a potential target for
anti-cancer drug development, we used a conditionalMycERTAM;Bcl-xLmodel of pancreatic
neuroendocrine tumorigenesis (PNET) to assess the role of cathepsin L in Myc-induced
tumor progression. By employing a cysteine cathepsin activity probe in vivo and in vitro, we
first established that cathepsin activity increases during the initial stages ofMycERTAM;Bcl-
xL tumor development. Among the cathepsin family members investigated, only cathepsin L
was predominately produced by beta-tumor cells in neoplastic pancreata and, consistent
with this, cathepsin LmRNA expression was rapidly upregulated following Myc activation in
the beta cell compartment. By contrast, cathepsins B, S and C were highly enriched in
tumor-infiltrating leukocytes. Genetic deletion of cathepsin L had no discernible effect on
the initiation of neoplastic growth or concordant angiogenesis. However, the tumors that de-
veloped in the cathepsin L-deficient background were markedly reduced in size relative to
their typical wild-type counterparts, indicative of a role for cathepsin L in enabling expansive
tumor growth. Thus, genetic blockade of cathepsin L activity is inferred to retard Myc-driven
tumor growth, encouraging the potential utility of pharmacological inhibitors of cysteine ca-
thepsins in treating late stage tumors.
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Introduction
Progression of normal cells into malignancies in humans is dependent upon acquisition of a
number of functional cancer “hallmarks” including uncontrolled proliferation, suppressed cell
death, increased invasion, angiogenesis, and reprogramming of biosynthetic metabolism [1].
However, the exact mechanisms by which tumors acquire these pathological attributes may be
highly variable and appears to depend on both tissue of origin and the specific oncogenic
mechanisms that drive each tumor.
The human cysteine cathepsins are family of 11 proteases, all of which share a conserved
active site [2]. Increased expression of cysteine cathepsins (CTS) is associated with the pro-
gression of different types of human cancers (reviewed in [3, 4]). Cysteine cathepsins are
well-documented mediators of lysosomal protein degradation [5] but, in addition, several ca-
thepsins are also implicated in a number of other physiological roles, some of which involve
altered subcellular localization, and secretion [3]. Among these ancillary non-lysosomal func-
tions are MHC class II-associated antigen processing and presentation [6], skin morphogene-
sis [7], heart function [8], and cytotoxic T-cell-induced apoptosis [9]. In cancer, cysteine
cathepsins have been identified as important contributors to tumor invasion, angiogenesis,
and metastasis [4], most notably CTS B and L. A role for cathepsin B in tumor invasion and
metastasis is well described [10, 11]: CTS B localizes to the invasive margin of tumors where it
is produced by tumor-associated inflammatory cells [12, 13]. CTS L activity has also been
demonstrated in various tumor types where it is a negative prognostic indicator in patients
with breast, colorectal and head and neck cancer [14]. However, the mechanism by which ca-
thepsin L modulates tumor progression is highly context-dependent [15] and remains contro-
versial. While in some settings CTS L has a clear pro-tumorigenic role [12, 16], in squamous
carcinomas CTS L deficiency actually promotes tumor progression [17], whereas in the APC-
min-driven model of colon cancer loss of CTS L results in increased tumor multiplicity [18].
For example, pharmacological inhibition of cathepsin L activity is anti-angiogenic in standard
in vitro angiogenesis assays [19] yet genetic deletion of CTS L has no effect on angiogenic
switching in pancreatic neuroendocrine tumors (PNETs) [12]. Similarly, suppression of ca-
thepsin L activity impairs invasion of glioma cells [16] but not melanoma cell lines [20].
Nonetheless, despite these disparate observations, cathepsin L is currently being evaluated as
a possible target in cancer therapy and this has fostered the development of numerous cathep-
sin L inhibitors (review in [15]). It is therefore important to establish for which tissue type,
stage of disease progression, and genetic constitution, inhibition of CTS L activity might have
therapeutic potential.
The protein product of the c-myc gene, c-Myc, is a highly pleiotropic transcription factor
that regulates expression of many, diverse genes [21]. Deregulation of the c-myc oncogene is
implicated in driving the relentless growth of many human cancers (for comprehensive re-
view see [22]) via its ability to drive many of the classical cancer hallmarks, including cell
growth and proliferation [23, 24], angiogenesis [25, 26] and invasion [27]. Each of these hall-
marks can be dissected in the synchronousMycERTAM;Bcl-xL reversibly switchable model of
Myc-induced beta cell tumor progression [28], a capability that has enabled us to assess the
contribution made by CTS L at different stages of Myc-driven tumorigenesis. The expression
of Bcl-xL anti-apoptotic protein is crucial in this model for Myc-induced tumorigenesis in
pancreatic islets, wherein it protects beta-cells from c-Myc-induced apoptosis [28]. Here we
describe genetic studies demonstrating that blockade of CTS L activity, while inconsequential
for the onset of tumor progression and exerts a profound anti-tumorigenic effect at later
stages of the disease.
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Results
Cysteine cathepsins are induced and activated in response to c-Myc
activation
Cysteine cathepsin proteases, particularly CTS B and L, are frequently upregulated in various
types of human cancers [29]. Moreover, in a protypical model of PNET progression—RIP1-
Tag2 (RT2)—increased expression and activity of a number of cysteine cathepsins strongly
correlate with advanced stages of tumorigenesis [30]. In the RT2 model, CTS B and S are
produced by infiltrating immune cells and are important factors in facilitating tumor inva-
sion. By contrast, CTS L is produced by the tumor cells and is critical for tumor maintenance
[12, 13].
Deregulated activity of transcriptional factor Myc is implicated in a large number of can-
cers and often associated with more aggressive tumors. We sought to establish whether Myc-
induced tumorigenesis in pancreatic endocrine tumors in vivo is associated with an increase
in cysteine cathepsin L, and to determine whether, and at what stage(s) of disease progression,
such CTS L might be functionally important. Activation of 4-OHT-dependent c-MycERTAM
in the beta-cell compartment of pancreatic islets of theMycERTAM;Bcl-xL model of pancreatic
neuroendocrine tumors (PNET) results in synchronous onset and progression of beta-cell
proliferation, culminating in highly angiogenic and invasive tumors [26, 28]. Following sys-
temic administration of tamoxifen (TAM), c-Myc is synchronously activated within 1–2
hours in all beta-cells, permitting facile temporal dissection of the ensuing stages of tumori-
genesis in vivo [24].
Analysis of a beta-cell Myc target gene database obtained from laser-capturedMycERTAM;
Bcl-xL islets following 2, 8, 24 hours and 21 days of Myc activation [24] revealed significant and
specific up-regulation of cathepsin LmRNA expression among the four cysteine cathepsin
genes expressed in theMycERTAM;Bcl-xL islets (Fig 1A). Such regulation by c-Myc is consistent
with the presence of a consensus Myc-binding E-Box (CACGTG) element at position -458 of
the cathepsin L promoter. We reason that the transient induction of CTS B, C and S reflects the
Myc-induced recruitment of infiltrating myeloid cells [[31, 32] and Fig 2].
To determine whether induction of CTS LmRNA expression in the early stages of Myc-in-
duced tumorigenesis correlates with increased cysteine cathepsin L enzymatic activity, we
used DCG-04, a chemical activity-based probe (ABP) specific to the cysteine cathepsins [30,
33]. DCG-04 is based on a small molecule scaffold that binds covalently in the active sites of
the cysteine cathepsins, allowing their specific identification in vitro and in vivo. Myc was ac-
tivated inMycERTAM;Bcl-xL mice for 3 or 7 days, corresponding to the early stages ofMycER-
TAM;Bcl-xL PNET tumor progression [26, 28]. To rule out the Myc-independent induction of
CTS expression in response to intraperitoneal injection of tamoxifen, we subjected control
Myc-negative Bcl-xL animals to seven-day treatment with TAM (S1 Fig). The pancreata were
harvested and cysteine cathepsin activity assayed with biotinylated DCG-04. Activities of
both cathepsin L and B were increased following c-Myc activation in vivo (Fig 1B). To moni-
tor cathepsin activity in intact animals in vivo we used a cell-permeable fluorescent analog of
DCG-04, incorporating the BODIPY fluorophore as a tag (BODIPY 530/550-DCG-04),
which was administered intravenously intoMycERTAM;Bcl-xL mice treatment 7 days. We de-
tected an increase in total cystein cathepsin activity in the hyperplastic islets following Myc
activation in vivo (Fig 1C), which was absent in TAM-treated Myc-negative control Bcl-xL
animals (Fig 1C). These data demonstrate that both CTS LmRNA expression and cysteine
cathepsin activity are elevated during the early stages of Myc-induced beta cell tumourigen-
esis in vivo.
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Cysteine cathepsin L, but not cathepsins B, C or S, is produced by tumor
cells
To determine the cellular source of Myc-induced cathepsin activity, Tamoxifen (TAM) was ad-
ministered toMycERTAM;Bcl-xL mice for 7 days and cathepsins then detected immunohisto-
chemically in pancreas tissue sections (Fig 2A—Myc-ON). Control animals were treated with
control vehicle in place of TAM (Myc-OFF). Levels of all tested cysteine cathepsins (B, C, L
Fig 1. Cysteine cathepsins are rapidly induced and activated in response to c-Myc. (A) Relative fold
mRNA induction of cathepsin B, C, L and S in laser-capturedMycERTAM;Bcl-xL pancreatic islets collected at
2, 8, 24 hours and 21 days following c-Myc activation in vivo. Only cathepsin L mRNA is significantly and
persistently upregulated following c-Myc activation. *p0.05 by one way ANOVA analysis. (B) Cathepsin
activity profiles for the pancreatic islets fromMycERTAM;Bcl-xL animals using DCG-04 ABP on tissue lysates.
The blot shows activity in untreated islets (OFF), which increases following administration of TAM (Myc-ON)
for 3 and 7 days. The activity bands corresponding to cysteine cathepsins (CTS) B, L and C are indicated.
The data are representative of two independent experiments. Three animals were used for islet purifications
at each data point. On the bottom, the graphical representation of cathepsin enzyme activity presented as
fold of induction relative to control. The bands intensities were quantified by NIH-FIJI software. The relative
expression of each cathepsin tested in the absence of Myc activation is assigned a value 1. (C) Labeling of
active proteases in vivo. A cell-permeable fluorescent analog of DCG-04 incorporating the BODIPY
fluorophore as a tag, BODIPY 530/550-DCG-04, was injected intravenously intoMycERTAM;Bcl-xL and Bcl-
xLmice untreated or treated with tamoxifen (TAM) for 7 days. Very little cathepsin activity was observed in
islets in non-treated animals (left panel) or Myc-negative control animals injected with TAM for 7 days (right
panel). However,MycERTAM;Bcl-xL animals had a profound increase in the cathepsin activity in the Myc-ON
hyperplastic islets (middle panel, indicated by arrows). Corresponding images of pancreata counterstained
with DNA-binding dye—DAPI are presented. The panels are representatives of at least three animals
assayed at each data point, immunohistochemical analyses done in triplicate; seven randomized fields per
analysis were considered. Scale bars are 20 μm. The islet area is indicated by the dotted line, I = islet. On the
bottom, the quantification of the mean intensity of the BODIFY fluorophore in the islet area quantified by
NIH-FIJI software. Statistical analysis was performed using the unpaired Student’s t test.
doi:10.1371/journal.pone.0120348.g001
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and S) were elevated in response to Myc activity. However, whereas CTS B, C and S expression
were in the main confined to the inflammatory (CD45-positive) compartment of pancreatic
tissue, cathepsin L was localized to the pancreatic islets of Langerhans. Furthermore, cathepsin
L expression was limited to the insulin-producing cells in the tumor tissue, indicating a beta-
cell origin of cathepsin L expression in theMycERTAM;Bcl-xL tumor model (Fig 2B). Moreover,
Fig 2. Myc induces cathepsin L expression in beta-cells of pancreatic Islets. (A) Immunohistochemical
analyses for CTS B, C, L or S expression (all in red) in combination with staining for the pan-leukocyte marker
CD45 (green) in pancreatic islet tumors from theMycERTAM;Bcl-xL animals. Pancreata were harvested from
theMycERTAM;Bcl-xLmice treated for 7 d with TAM (Myc-On, 7 days) or control vehicle in place of TAM
(Myc-OFF). The islet area is indicated by dotted line. The asterisks indicate the area of tumor represented in
the insets. The panels are representatives of at least three animals assayed at each data point, all
immunohistochemical analyses were done in duplicate; eight randomized fields per analysis were examined.
Scale bars, 100μm. (B) Immunohistochemical analysis for cathepsin L expression in beta-cells of pancreatic
islets fromMycERTAM;Bcl-xL animals identified by insulin expression. Pancreata were collected from the
animals described above. Scale bars represent 25μm. The panels are representatives of three animals
assayed at each data point, all immunohistochemical analyses were done in duplicate; ten randomized fields
per analysis were examined.
doi:10.1371/journal.pone.0120348.g002
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loss of CTS L activity in bone marrow derived cells in the RT2 PNET model had no impact on
the number of developed tumors, tumor volume, or tumor invasion [13]. Hence, cathepsin L is
expressed and activated in the cancer cells of Myc-driven PNETs in vivo.
Inhibition of cysteine cathepsin L activity has no significant impact on
early stages of c-Myc-induced tumorigenesis
Progression of c-Myc-induced PNET tumorigenesis is accompanied by the recruitment of a va-
riety of inflammatory cells to the neoplastic site, which serve to support tumor growth, angio-
genesis and invasion [31, 32]. The tissue microenvironments of the RT2 and theMycERTAM;
Bcl-xLmodels appear to have similar properties [32], and macrophage-supplied cathepsins B
and S are most likely to contribute to PNET invasion in both theMycERTAM;Bcl-xL and RT2
models [13]. However, tumor cell intrinsic events, including Myc-mediated regulation of ca-
thepsin L expression, might be different between these two models, as the RT2 and theMycER-
TAM;Bcl-xL PNET cancer cells are driven by distinct oncogenes, the SV40 antigen and activated
c-Myc, respectively.
To determine the role of CTS L activity duringMycERTAM;Bcl-xL PNET progression, we
bred theMycERTAM;Bcl-xL animals into the cathepsin L-deficient background. The resulting
MycERTAM;Bcl-xL;Cathepsin L KO (MycERTAM;Bcl-xL;CTSLKO) animals were phenotypically
similar to CTSL KO littermates [7] in the absence of c-MycERTAM activation. To assess the ef-
fect of CTS L-deficiency on the early stages of Myc-induced beta-cell tumourigenesis,Myc;Bcl-
xL;CTSLKO andMyc;Bcl-xL animals were subjected to treatment with TAM for the duration
of three days. This treatment induced proliferation in the beta-cell compartment of pancreatic
islets accompanied by tumor angiogenesis [26], which was independent of CTS L status (Fig
3A). In addition, the percentage of proliferating endothelial cells, was unaffected by cathepsin
L deficiency (Fig 3A). Moreover, in vivo administration of a broad-spectrum inhibitor of cyste-
ine cathepsin activity—JPM-OEt [34]—for a 5-day duration had no impact on the Myc-medi-
ated sequestration of extracellular-matrix-bound VEGF into the endothelial compartment of
the pancreatic islets (S2A Fig), the initiating step in PNET angiogenesis [26, 35]. Our data im-
plies that CTS L activity is not essential for the initiation of tumor angiogenesis in the Myc-
driven model of PNET. One of the downstream targets of cysteine cathepsin proteolysis in the
RT2model is the cell-cell adhesion glycoprotein E-cadherin [12]. E-cadherin is the major adhe-
sion molecule in epithelia [36, 37]. Loss of E-cadherin, common in cancers, is a prerequisite for
beta-cell invasion and metastasis in the RT2 model [38]. In theMycERTAM;Bcl-xLmodel, E-
cadherin downregulation by Myc correlates with the abrupt loss of intercellular contacts within
the islet, macroscopic islet expansion, and local invasion of the pancreas [28]. Immunohisto-
chemical analysis of E-cadherin expression in theMyc;Bcl-xL pancreatic islets revealed rapid
and sustained loss of cell surface E-cadherin staining within the pancreatic islets following
three days of c-Myc activation, independent of cysteine cathepsin activity (S2B Fig), suggesting
that the requirements for Myc-induced CTS L activity in theMyc;Bcl-xLmodel might be dis-
tinct from those in the RT2 model.
Several contrasting reports implicate cathepsin L as either a positive [39, 40] or a negative
[16] regulator of the anti-apoptotic factor Bcl-xL. As noted above, expression of this anti-apo-
ptotic protein is necessary for Myc-induced tumorigenesis in pancreatic islets, wherein it pro-
tects beta-cells from c-Myc-induced cell death ([28] and Fig 3B). Following a three-day-
activation of Myc in vivo, the Bcl-xL protein levels remained unchanged in theMycERTAM;Bcl-
xL;CTSLKO islets when compared to the tissue collected from the CTSLWT;MycERTAM;Bcl-xL
animals. Moreover, histopathological analysis of the pancreata collected fromMycERTAM;Bcl-
xL;CTSLKO,MycERTAM;Bcl-xL andMycERTAM-only (Bcl-xL transgene-negative) animals
Role of Cathepsin L in Myc-Induced Tumorigenesis
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following three days of Myc-activation revealed that while the Bcl-xL-negative Myc-expressing
islets rapidly involute following Myc-activation as described in [28], Myc-activation had no
profound effect on the morphology of theMycERTAM;Bcl-xL;CTSLKO islets (S3 Fig). In sum-
mary, our data suggest that inhibition of cathepsin L activity both by genetic and pharmacolog-
ical means has no significant impact on the onset of Myc-induced tumorigenesis in vivo.
Loss of cathepsin L inhibits late stages of PNET progression
Since CTS L activity was not crucial for the initiation of Myc-driven PNET tumorigenesis, we
proceeded to investigate whether sustained inactivation of CTS L modulates later stages of
tumor progression. Activation of MycERTAM for the duration of two weeks in theMycERTAM;
Bcl-xLmodel triggers rapid and uniform progression of islets into invasive tumors [28]. We
therefore subjected theMycERTAM;Bcl-xLmice from the cathepsin L-deficient, cathepsin L-
Fig 3. Loss of cathepsin L does not inhibit onset of Myc-induced tumorigenesis. (A)
Immunohistochemical analysis of endothelial cell proliferation in vivo. Pancreata was isolated from the
MycERTAM;Bcl-xL animals from CTS LWT and CTS L-deficient backgrounds untreated or treated with TAM
for the duration of three days. Proliferating endothelial cells were identified by co-labeling with the endothelial
marker Meca-32 (green) and Ki67 (red). The islet area is outlined by dotted lines. The asterisks indicate the
magnified areas of the endothelial compartment of islets presented in the insets. The percentage of Meca-
32-positive cells that also stained positive for the proliferation marker Ki67 was then determined as described
in Materials and Methods section. At least three animals were assayed of each genotype all analyses done in
duplicate; ten randomized fields per analysis were considered. The graph shows the mean and standard
error of the mean. ns—no statistical significant difference was detected by Student’s T-test analysis. Scale
bars, 25μm. (B) Representative H&E staining of pancreatic sections fromMycERTAM,MycERTAM;Bcl-xL and
MycERTAM;Bcl-xL;CTSLKO collected from animals subjected to Myc activation for 3 days. Induction of Myc in
the pancreatic islets lacking Bcl-xL expression (Myc) induces profound apoptosis and ablation of the islet
beta-cell compartment as described in [28] (right panel). Loss of cathepsin L inMycERTAM;Bcl-xL;CTSLKO
(middle panel) has no significant impact on morphology of pancreatic islets following onset of Myc-induced
tumorigenesis when compared toMycERTAM;Bcl-xL islets (left panel). At least three animals of each
genotype were assayed, eight randomized fields per analysis were considered. Scale bars, 25μm.
doi:10.1371/journal.pone.0120348.g003
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heterozygous and cathepsin L-competent backgrounds to treatment with TAM for fourteen
consecutive days (Myc-ON). While cathepsin L-deficiency had no profound effect on pancre-
atic tissue pathology in the absence of MycERTAM activation (Fig 4A), or following three-day
exposure to TAM (Fig 3B) when compared to cathepsin L wild-type (WT) counterparts, the
formation of Myc-induced invasive carcinomas following two-week exposure to TAM was sig-
nificantly impaired by the absence of cathepsin L (Fig 4A). Specifically, an analysis of tumor
size performed as described in Materials and Methods section, established that the area of the
MycERTAM;Bcl-xL;CTSLKO lesions noted on H&E-stained sections was 1.2% (+/-0.37%) of tu-
mors collected from theMycERTAM;Bcl-xLmice. We observed no dosage-specific effect of ca-
thepsin L deficiency, as CTSL heterozygous animals developed tumors indistinguishable in
their histopathological features from the lesions arising from the CTSLWT background. In-
triguingly, we detected a profound deficit in Myc-induced beta-cell proliferation in CTSL-defi-
cient animals after 2-weeks of MycERTAM activation (0.19% of proliferating tumor cells in the
CTSLKOmice compared to 21.6% in the CTSL WT lesions) (Fig 4B) that was not apparent in
Fig 4. Loss of cathepsin L inhibits Myc-induced tumorigenesis in theMycERTAM;Bcl-xL pancreatic
neuroendocrine cancer model. (A) Histopathological analysis by H&E staining of pancreatic
neurodendocrine tumors from theMycERTAM;Bcl-xL andMycERTAM;Bcl-xL;CTSLKO animals untreated
(Myc-OFF) or treated with TAM for 14 days (Myc-ON, 14 days). The tumor area is outlined by dotted lines.
Images represent pancreata collected from three animals of each genotype. Pancreata collected from
animals that retain one functional cathepsin L allele—Myc;Bcl-xL;CTSLHET (CTSL+/-) are presented as a
control. Four animals of each genotype were assayed; at least 17 tumors for each genotype were analyzed.
Scale bars, 200μm. On the bottom, graph shows quantification of pancreatic islet volume calculated using
FIJI software as described in Materials and Methods section. Statistical significance was assessed using the
Student T-test). (B) Immunohistochemical analysis of insulin (green) and proliferation marker KI67 (red) in
pancreata collected fromMycERTAM;Bcl-xL andMycERTAM;Bcl-xL;CTSLKO animals treated as described
above. The tumor area is outlined by dotted lines. The asterisks indicate the enlarged areas presented. †—
Non-specific staining due to tissue autofluorescence. Three animals of each genotype were assayed; all
analyses done in duplicate; six randomized fields per analysis were considered. Scale bars, 100μm.
doi:10.1371/journal.pone.0120348.g004
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the early premalignant stages of Myc-induced tumorigenesis in theMycERTAM;Bcl-xL;CTSLKO
mice (Fig 3A).
Loss of cathepsin L alters expression of markers of autophagy and
apoptosis in Myc;Bcl-xL tumors
Cathepsin L is a lysosomal endopeptidase that has been reported to be present inside cellular
lysosomes, as well as in the lysosomal membrane [41]. Cathepsin L localization, as well as the
cell type of origin, may significantly alter the range of cathepsin L substrates and their contribu-
tion to cancer progression. We hypothesized that in PNET tumors, the loss of cathepsin L ac-
tivity negatively impairs fusion between the lysosomal and autophagosomal compartments of
the cell, resulting in the accumulation of cellular autophagosomes. We therefore investigated
whether expression of autophagic markers is altered in the CTS L-deficient tumors. The LC3
protein is a mammalian homologue of yeast factor Apg8p that is essential for autophagy [42].
The conversion of soluble LC3-I to lipid bound LC3-II is associated with the formation of
autophagosomes, which can be monitored by the appearance of punctate staining in the tissue.
An immunohistochemical analysis of LC3 expression in the pancreata collected from the
MycERTAM;Bcl-xL andMycERTAM;Bcl-xL;CTSL-deficient animals subjected to 14 days of Myc-
activation in vivo revealed a significant increase in the punctate pattern of LC3 expression in
the CTSLKO tumors (Fig 5A). However, despite the apparent increase in the autophagosome
count in CTS L KO tumors, the detected autophagosomes were not fused with cellular lyso-
somes. Confocal microscopy analysis of the pancreata collected following Myc activation for
the duration of 14 days (Fig 5B) demonstrated that only 3.6% CTS L-deficient LC3+ vehicles
versus 16.36% CTSLWT LC3+ vehicles were co-localized with lysosomes identified by LAMP-
1 expression (Fig 5B). Depending on the cell of origin and oncogenic drivers, the loss of cathep-
sin L in tissue could negatively or positively contribute to tumor cell survival [12] [17, 18]. We
proceeded to investigate the effect of CTS L loss on the survival of tumor cells in the Myc-driv-
en PNET. TheMycERTAM;Bcl-xL andMycERTAM;Bcl-xL;CTSL-deficient animals were sub-
jected to treatment with TAM for the duration of 1, 3 and 14 days. The pancreata from the
treated animals were collected and analyzed for the expression of activated caspase 3, a marker
of apoptosis. Deletion of cathepsin L in Myc-driven PNET significantly increased tumor cell
death, and was more apparent during the late stages of tumor progression (Fig 5C). In summa-
ry, our data suggests that loss of CTS L in the Myc-induced tumors results in a profound
growth impairment of lesions associated with the accumulation of autophagosomes, and an in-
crease in apoptotic cell death.
Discussion
Efforts to determine the contributing roles of active cysteine cathepsin L to the progression of
human malignancies have produced opposing results [15]. In order to evaluate cathepsin L as a
potential target in cancer therapies, it will be crucial to establish its role in each type of cancer
and stage of tumor progression. The current study addresses the role of cysteine cathepsin L in
Myc-driven neuroendocrine tumorigenesis. Activation of Myc is proposed to be an early event
in human PNET progression [43].
The elevated activity of cysteine cathepsins appears to be a common event in PNET progres-
sion, as it has been observed in both the currently presentedMycERTAM;Bcl-xLmodel and pre-
viously in the RT2model [30]. In addition, c-Myc directly induces cysteine cathepsin activity,
which highlights the importance of these enzymes in PNET tumorigenesis. Our data suggest
that increased cysteine cathepsin enzyme activity in c-Myc-driven tumorigenesis is mediated
by two distinct mechanisms. While some family members such as cathepsins B, C and S, are
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Fig 5. Loss of cathepsin L in Myc-induced pancreatic neuroendocrine tumors is associated with the
elevated expression of markers of cell autophagy and apoptosis in vivo. (A) Immunohistochemical
analysis of LC 5 expression in the pancreata collected from theMycERTAM;Bcl-xL andMycER
TAM;Bcl-xL;
CTSLKO animals untreated (Myc-OFF) or treated with TAM for the duration of 14 days (Myc-ON (14 days)).
At least four animals were assayed for each genotype; immunohistochemical analyses done in duplicate; ten
randomized fields per analysis were considered. The asterisks indicate areas of tumor tissue enlarged in the
inset in the upper right corner. Note punctate LC3 staining in theMycERTAM;Bcl-xL;CTSLKO animals. The
graph shows quantification of LC3 puncta per cells in described tumors (n = 4 (Myc; BclXL mice) and n = 3
(Myc, Bcl Xl, CTSL mcie) at least eight independent fields for animal were considered). Statistical analysis
was done by unpaired Student’s t test. Scale bars, 50 μm. (B) Immunohistochemical analysis of intracellular
localization of LC-3 and the lysosomal marker LAMP1 in pancreata collected from theMycERTAM;Bcl-xL and
MycERTAM;Bcl-xL;CTSLKO animals treated with TAM for the duration of 14 days determined by confocal
microscopy (See Materials and Methods). White arrows marked the arrears of co-localization of LC3 and
LAMP1 staining. At least three animals were assayed for each genotype; immunohistochemical analyses
done in duplicate; nine randomized fields per analysis were considered. Graph shows LC3+ and LAMP1+ co-
localization presented as the percentage of total LC3+ dots. *** p<0.0001 by the two-tailed Student’s t test.
(C) Representative images from an IHC analysis of apoptosis assayed by activated caspase-3 (CC-3)
staining in pancreata collected from the theMycERTAM;Bcl-xL andMycER
TAM;Bcl-xL;CTSLKO animals
treated with control vehicle (Myc-OFF) or TAM for the duration of 1, 3 or 14 consecutive days. Islet area is
outlined by dotted line. At least three animals were assayed for each genotype and time point. Graph shows
quantification of CC3+ cells in islet area. Scale bars = 50 μm.
doi:10.1371/journal.pone.0120348.g005
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supplied to the PNET tumor site by CD45+ inflammatory cells, cathepsin L is predominantly
expressed by insulin-producing cancer cells. The recruitment of inflammatory cells to the
tumor site in theMycERTAM;Bcl-xL PNET model is directed by c-Myc-induced expression of a
variety of cytokines, and is crucial for tumor invasion and maintenance of the tumor-blood
supply [31, 32]. It is possible that some of these functions are mediated by lysosomal proteases
that may translocate to the cell surface and are secreted outside of the cell. In the extracellular
environment, cysteine cathepsins were implicated in the degradation of ECM components [3,
12, 13, 30]. However, tumor cell-supplied cathepsin L appears to function intracellularly, as
suggested by this study and others [12, 18].
In contrast to the constitutive RT2 PNET model, a conditionalMycERTAM;Bcl-xLmodel en-
ables the examination of individual stages in multi-step tumor progression. Surprisingly, none
of the features associated with the early stages of c-Myc-induced tumorigenesis in PNET, such
as c-Myc-induced beta-cell proliferation, initiation of tumor angiogenesis, or acute loss of E-
cadherin expression, was affected by deficiency in cathepsin L activity. Interestingly, in melano-
ma and breast cancer xenograft models, loss of cathepsin L activity impaired tumor angiogene-
sis [19, 44], whereas in two independent models of PNET progression, loss of cathepsin L had
no effect on the onset of tumor angiogenesis ([12] and this study). It is possible that the con-
tributing role of cathepsin L to the regulation of angiogenesis depends on the timing, and the
extent of the blood supply coverage in the particular tumor type.
The distinction between tumor initiating lesions and factors required for tumor mainte-
nance is an important issue in tumor biology. In the constitutive model of PNET progression
—RT2—the proliferation rate in advanced stages of tumor progression (insulinomas and inva-
sive carcinomas) in the cathepsin L-deficient background was significantly reduced by ~90%
when compared to control tumors with WT CTS L [12]. In theMycERTAM;Bcl-xLmodel, defi-
ciency in cathepsin L activity also had a profound effect on late stages of disease progression,
manifested by ~97% of growth inhibition and partial collapse of the developed lesions. We con-
clude that cathepsin L is required for tumor maintenance and progression, rather than tumor
initiation, during neuroendocrine tumorigenesis involving Myc-driven proliferation.
Highly proliferative tumor cells require a constant supply of nutrients to support growth,
usually achieved by increased uptake of glucose and a high glycolytic rate. C-Myc orchestrates
tumor metabolic adaptation by several mechanisms, including upregulation of the glucose
transporter Glut-1, induced over-expression of metabolic enzymes, and the use of alternative
sources of energy such as glutamine [45, 46]. In addition, c-Myc is reported to regulate tumor
cell autophagy both in vitro and in vivo [47, 48]. On the one hand autophagy can have a tumor
suppressive effect, by targeting proteins and organelles damaged by increased reactive oxygen
species associated with activated oncogenes [49, 50]. Alternatively, accumulating evidence sug-
gests that this evolutionary conserved process can promote the growth of established malignan-
cies by providing tumor cells with a mechanism to generate alternative sources of metabolic
fuel via protein and membrane recycling [51, 52]. Thus, in cells that depend on autophagy for
survival, inhibition of autophagy by chloroquine [51] or knockdown of the lysosomal protein
LAMP-2 [53] leads to the accumulation of defective autophagosomes and cell death.
To our knowledge, the work presented herein is the first report demonstrating a link be-
tween the c-Myc oncogene and the lysosomal protease cathepsin L in tumor cells in vivo. We
show that deletion of cathepsin L in Myc-driven pancreatic neoplasias results in both a reduc-
tion in autolysosomal formation and an increase in tumor cell death. Though our current data
does not formally demonstrate a causal relationship between cathepsin L deletion and alter-
ation of autophagy in Myc-driven lesions, or that the increase in tumor cell death detected in
late stages of tumor progression in theMycERTAM;Bcl-xL;CTSL-deficient neoplasias is a direct
consequence of altered autophagic flux in vivo, it is reasonable to suggest that these events are
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intertwined [54]. The exact sequence of events underlying cathepsin L-mediated regulation of
cell autophagy and cell death in Myc-driven PNETs shall be a subject of future investigations.
Nonetheless, we propose that combining inhibitors of cathepsin L with other factors targeting
tumor cell autophagy may have therapeutic potential for Myc-driven malignancies at advanced
stages of progression, when autophagy evidently becomes important for sustaining robust cell
proliferation and tumor growth.
Materials and Methods
Mice, tissue sample generation, manipulation and preparation
This study was approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of California, San Francisco, protocol number AN076148. The transgenic mice ex-
pressing switchable MycERTAM and constitutive Bcl-xL in their pancreatic β cells pIns-MycER-
TAM;RIP7-Bcl-xL (MycER
TAM;Bcl-xL) mice have been previously described and characterized
[28]. MycERTAM was activated in beta-cells in situ by daily i.p. injection of Tamoxifen (TAM)
(1mg/mouse/day) dissolved in peanut oil (Sigma). TAM is metabolized in vivo to 4-OHT and
has an equivalent effect to 4-OHT when administered toMycERTAM;Bcl-xLmice. The cathepsin
L deficient animals were previously reported [7]. In vivo labeling and detection of cathepsin activ-
ity with BODIPY 530/550-DCG-04 was performed as described [30]. For inhibition of cathepsin
activity in vivo, the animals were subjected to 50mg/kg/day injection with the inhibitor JPM-OEt
or control vehicle (30% DMSO/70% PBS) in conjunction with TAM injections for the duration
of 5 days as previously described [30]. The animals were euthanized by exposure to CO2.
Histology and immunohistochemistry
Briefly, paraffin-embedded sections (10 μm) were deparaffinized and rehydrated in a series of
graded alcohols and blocked for endogenous peroxidase activity. Antigen retrieval was per-
formed in 10 mM sodium citrate (pH 6.0). Endogenous peroxidase activity was blocked with
3% H2O2 in tap water for 5 minutes. Avidin/Biotin blocking and blocking of endogenous
mouse immunoglobulins in the tissue were performed respectively by Vector Avidin/Biotin
blocking kit (SP-2001) and Vector MOM basic kit (Cat. No. BMK-2202), both were used ac-
cording to the manufacture’s protocols. The primary antibody used: anti-LC3 5F10 mAb
(nanoTools, 1:100). Sections were incubated with ABC reagent VACTASTAIN Elite ABC Stan-
dard Kit (PK-6100) and developed with diacylbutyrate (DAB). DAB-stained slides were coun-
terstained lightly with hematoxylin.
For the OCT-embedded tissues, 10 μm sections were fixed in 1% paraformaldehyde. The
primary antibodies used: anti-mouse VEGF A (RDI-mVEGFabrP1, RDI), anti-Meca-32
(550563, BD Pharmingen), anti-Ki67 (ab16667, Abcam), anti-murine CD45 (550539, BD
Pharmingen), rabbit polyclonal anti-LAMP1 (ab24170, Abcam), rabbit polyclonal anti-active-
caspase 3 (AF 835, R&D), and anti-cystein cathepsins antibodies—Cathepsin B (AF965), Ca-
thepsin S (AF1183), Cathepsin C (AF1034), and Cathepsin L (AF1515) (all from R&D Sys-
tems). All were applied in blocking buffer (2.5% BSA, 5% donkey serum) for 2–16 hours.
Secondary antibodies were from Dako and Molecular Probes. The cells were counterstained
with DNA-binding dye—DAPI (1-236-276-001, Roche, Mannheim, Germany).
Fluorescent images were obtained using Axiovert 100 inverted microscope (Zeiss) or Leica
DM5500 microscope with cameras DFC360X (fluorescent detection) and DFC 295 (colorimet-
ric detection). Confocal images were obtained using a LSM 700 (Zeiss). Immunohistochemical
analysis for each antigen was performed at least in duplicate. The quantitative analyses of
immmunostained sections were performed automatically by Fuji NIH software, with algo-
rithms provided by the Bioimaging and Optics platform at EPFL.
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Endothelial cell proliferation was quantified in tissue sections by counting randomized fields
of endothelial cells (Meca32+) and calculating the percentage of Ki67+ cells. At least three ani-
mals were assayed of each genotype all analyses done in duplicate; ten randomized fields per
analysis were considered. Statistical significance was assessed using the Student T-test.
Analysis of size was performed with the Fiji Software package (http://rsb.info.nih.gov/ij) as
follows. Ten serial H&E-stained sections of the entire pancreata from the tumor-bearing animals
were scanned with a Leica DM5500 at 20x magnification. The tumors were manually outlined
with Freehand Selection tool. The software then calculates the outlined area. At least 17 tumors
for each genotype were analyzed. Each collected tumor was treated as an independent event.
Analysis of BODIFY fluorophore mean intensity was performed with the Fiji Software package.
The tumors were manually outlined with Freehand Selection tool. The software then calculates
the mean intensity of the selected area. At least eight tumors for each treatment were analyzed.
Analysis of cathepsin activity in vitro
For in vitro analysis, the islets collected as described [26] were homogenized on ice in lysis buff-
er (50mM acetate buffer [pH 5.5], 5mM DTT, 5mMMgCl2, 0.1% Triton X-100). Protein con-
centration was established by the Bradford assay. The equal amount of protein lysates were
labeled with biotinylated DCG-04 ABP [30] equally loaded, and analyzed by gel electrophoresis
as previously described [33].
Laser-capture microdissection, Affymetrix GeneChip Arrays, data
analysis and promoter analysis
These procedures were described in [24].
Statistical analysis and quantification of immune-stainings
Data were presented as the means ± standard error of the mean (SEM). The statistical analysis
was calculated using GraphPad Prism5 software package. The quantification of tumor prolifer-
ation and apoptosis was performed by the Fiji Software package (http://rsb.info.nih.gov/ij) ac-
cording to algoriphm defined by Bioimaging & Optics platform (PT-BIOP) at EPFL.
Supporting Information
S1 Fig. Increased cathepsin activity detected following tamoxifen-treatment in vivo is re-
stricted to theMycERTAM-expressing islets. Cathepsin activity profiles for the pancreatic islets
fromMycERTAM;Bcl-xL and control Bcl-xL background animals using DCG-04 ABP on tissue
lysates. The blot shows activity in untreated islets (OFF), which increases following administra-
tion of 4-OHT (Myc-ON) at the timepoints indicated. Two independent islet purifications are
presented forMycERTAM;Bcl-xL animals treated for 7 days. The activity bands corresponding
to cysteine cathepsins (CTS) L, B and C are indicated. Molecular weight marker is indicated on
the side panel. Note the lack of cathepsin L and cathepsin B activation in samples collected
from control Bcl-xL background animals.
(TIF)
S2 Fig. Inhibition of Cathepsin activity in vivo. (A) Inhibition of cathepsin activity does not
interfere with Myc-induced redistribution of VEGF-A in islets.MycERTAM;Bcl-xL animals were
either untreated or treated daily with TAM for 5 days in conjunction with control vehicle
(DMSO) or the broad spectrum cathepsin inhibitor JPM-OEt (JMP). At the times indicated,
animals were sacrificed and pancreata isolated, sectioned and stained with anti-VEGF-A anti-
body (red) and Meca-32 (green). Images collected from two independent animals are
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presented. The panels are representatives of at least three animals assayed at each data point,
immunohistochemical analyses done in duplicate; seven randomized fields per analysis were
considered. Scale bars represent 100 μm. (B) Immunohistochemical analysis of E-cadherin in
the pancreata collected from the animals described above. The areas positive for E-cadherin ex-
pression in inhibitor-treated mice are indicated by arrows. I-islet area is outlined by dotted
line. The panels are representatives of at least three animals assayed at each data point, immu-
nohistochemical analyses done in duplicate; five randomized fields per analysis were consid-
ered. Scale bars represent 20 μm.
(TIF)
S3 Fig. Loss of cathepsin L does not affect the levels of Bcl-xL expression inMycER
TAM;Bcl-
xL islets. Immunohistochemical analysis of Bcl-xL expression in pancreatic tissues collected
fromMycERTAM;Bcl-xL andMycER
TAM;Bcl-xL;CTSLKO animals subjected to 3-day-treatment
with TAM. (Myc-ON, d3). Tissues collected fromMycERTAM;CTSLWT islets were used as a
negative control for the staining. Three animals were assayed of each genotype; seven random-
ized fields per analysis were considered. Scale bars represent 50 μm.
(TIF)
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